JW Pharmaceutical Corporation (001060-KS) Stock Split, History Data
Working capital analysis
In terms of working capital, JW Pharmaceutical Corporation maintains a healthy position.
The total current assets of the company are valued at $378091350382.
This represents a growth rate of -11.133% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $15908868301, exhibiting a growth rate of -53.068% year-on-year.
The receivables, another significant portion of the current assets, are valued at $173629305565.
The year-on-year growth rate for receivables is 7.082%.
The inventory, which forms a critical part of the assets, is valued at $106091353778.
This represents a healthy year-on-year growth of -4.994%
On the liabilities side, the company's current liabilities total $286927113694.
This reflects a growth rate of -24.519% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
15908.87
33897.93
33366.48
10451.34
41864.25
30948.42
Receavebles
173629.31
162146.19
192840.01
132743.50
189013.37
234798.74
Inventory
106091.35
111668.43
102527.60
101197.79
90442.49
101367.13
Other
5532.66
1963.72
5417.83
10096.27
13737.34
6795.79
Total Current Assets
378091.35
425457.06
366451.50
299328.71
335057.45
373910.08
Acc Payable
73847.21
82907.88
51642.85
47885.39
45087.22
44464.61
Short Term Debt
117404.62
207693.01
123074.57
107315.68
155880.77
128030.97
Other Current Liab
89585.37
82814.89
35045.58
42299.85
37271.21
47181.07
Current Liabilities
286927.11
380131.10
282677.56
234747.63
277983.38
228368.45
Capital Structure
When examining the capital structure of JW Pharmaceutical Corporation, it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $645038796101.
When juxtaposed with the previous year, this marks a growth rate of 2.718%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $379598339300.
Compared to the prior year, this reflects a growth rate of -5.623%.
The long-term debt forms a sizable part of these liabilities, coming in at $30000000000.
Over the last year, the long-term debt has grown by 1522.228%.
On the asset side, the cash and equivalent reserves are worth $15908868301.
The year-on-year growth of these reserves is -53.068%.
The company's common stock, another important asset, holds a value of $57925902500, growing at a rate of 4.474% from the previous year.
Finally, the company's retained earnings stand at $92612038000, marking a growth rate of 3.907% year-over-year.
These earnings represent the profits that JW Pharmaceutical Corporation has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$645,038.80
Total liabilities
$379,598,339,300.00
Long term debt
$30,000.00
Cash and eqv
$15,908,868,301.00
Goodwill
$1,404.47
Retained earnings
$92,612,038,000.00
Common stock
$33,578.95
Enterprise Value
$1.95
Historical dividend key summary
JW Pharmaceutical Corporation's dividend per share is $400, showing the earnings shared with shareholders per share. It has grown by 144.689% this year, suggesting that the company is generating increased income for shareholders and expecting future earnings growth.
Years
Q1
Q2
Q3
Q4
Total
2023
0.000
356.939
0.000
400.000
756.939
2022
0.000
309.347
0.000
0.000
309.347
2021
0.000
291.589
0.000
0.000
291.589
2020
0.000
291.589
0.000
0.000
291.589
2019
0.000
283.096
0.000
0.000
283.096
2018
0.000
234.846
0.000
0.000
234.846
2016
0.000
0.000
0.000
205.206
205.206
2015
0.000
0.000
0.000
117.261
117.261
2014
0.000
0.000
0.000
93.064
93.064
2013
0.000
0.000
0.000
88.632
88.632
2012
0.000
0.000
0.000
88.632
88.632
2011
0.000
0.000
0.000
135.059
135.059
2010
0.000
0.000
0.000
187.322
187.322
2007
0.000
0.000
0.000
176.569
176.569
Net earnings per share (EPS)
JW Pharmaceutical Corporation has an EPS of $1428.63, which signifies the profit allocated per share of common stock. With a growth rate of 3.207% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years
Q1
Q2
Q3
Q4
Total
2023
630.19
531
-767.96
1035.4
1428.63
2022
424.91
43.55
367.58
548.2
1384.24
2021
163.07
-136.68
206.43
-276.66
-43.84
2020
-99.75
-344.09
118.97
-326.52
-651.39
2019
-200.8
64.86
48.87
-1090.64
-1177.71
2018
175.96
331
84.49
-345.95
245.50
2017
28.18
-53.8
222.89
-299.79
-102.52
2016
54.42
-713.33
-207.64
410.18
-456.37
2015
11.96
-16.74
45.45
37.14
77.81
2014
61.51
-250.6
15.95
231.96
58.82
2013
39.78
51.35
31.82
6.01
128.96
2012
15.84
-618.54
-124.67
-584.01
-1311.38
2011
90.53
40.02
-259.12
-
-128.57
2010
349.65
89.8
51.59
-129.5
361.54
2009
330.2
231.88
-61.22
226.5
727.36
2008
289.06
283.96
10.21
-235.79
347.44
2007
364.96
401.98
189.95
-315.34
641.55
Brief information
JW Pharmaceutical Corporation (001060.KS) stock split history
Understanding the historical stock splits of JW Pharmaceutical Corporation (001060.KS) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on December 27, 2023 with a ratio of 1:1. Throughout its history, the company has undergone 19 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
